Masuda Muneyuki, Ruan Hong-Ying, Ito Aya, Nakashima Torahiko, Toh Satoshi, Wakasaki Takahiro, Yasumatsu Ryuji, Kutratomi Yuichiro, Komune Shizuo, Weinstein I Bernard
Department of Otorhinolaryngology, Kyushu Koseinenkin Hospital, 2-1-1, Kishinoura, Nishiku, Kitakyushu 806-8501, Japan.
Oral Oncol. 2007 Sep;43(8):785-90. doi: 10.1016/j.oraloncology.2006.10.007. Epub 2006 Dec 13.
Overexpression of vascular endothelial growth factor (VEGF) is associated with angiogenic phenotypes and poor prognosis of numerous tumors, including head and neck squamous cell carcinoma (HNSCC). However, the precise mechanism that causes VEGF overexpression in HNSCC remains unknown. Since there is evidence that a transcriptional factor, signal transducers and activators of transcription 3 (Stat3), is constitutively activated in HNSCC and this activation is significantly associated with aggressive phenotypes of this disease, we investigated the roles of Stat3 activation on VEGF production and tumor angiogenesis in HNSCC both in vitro and in clinical samples. VEGF promoter assays with YCU-H891 cells demonstrated that dominant negative Stat3 significantly inhibited VEGF promoter activity in the full length (-2279 to +54) and two truncated forms of VEGF promoter luciferase-reporter construct (-1179 to 54) or (-1014 to +54), which retain the putative Stat3 responsive elements (-849 to -842). However, this was not seen in the shorter construct (-794 to +54), which lacks the putative Stat3 responsive elements. In the derivative of YCU-891 cells that stably express dominant negative Stat3 protein, cellular levels of VEGF mRNA and VEGF protein were significantly inhibited. In the 51 clinical samples obtained from the patients with tongue carcinoma, the expression levels of phosphorylated (activated) form of Stat3 protein were significantly correlated with VEGF (P<0.05) production and intratumoral microvessel density IMVD (P<0.01). These results strongly indicate that Stat3 directly up-regulates VEGF transcription and thereby promotes angiogenesis in HNSCC. Inhibition of Stat3 activity may provide a new anti-angiogenic therapy in HNSCC.
血管内皮生长因子(VEGF)的过表达与包括头颈部鳞状细胞癌(HNSCC)在内的多种肿瘤的血管生成表型及不良预后相关。然而,HNSCC中导致VEGF过表达的确切机制仍不清楚。由于有证据表明转录因子信号转导子和转录激活子3(Stat3)在HNSCC中持续激活,且这种激活与该疾病的侵袭性表型显著相关,我们在体外和临床样本中研究了Stat3激活对HNSCC中VEGF产生和肿瘤血管生成的作用。用YCU-H891细胞进行的VEGF启动子分析表明,显性负性Stat3显著抑制全长(-2279至+54)以及VEGF启动子荧光素酶报告基因构建体的两种截短形式(-1179至54)或(-1014至+54)中的VEGF启动子活性,这两种截短形式保留了假定的Stat3反应元件(-849至-842)。然而,在缺乏假定的Stat3反应元件的较短构建体(-794至+54)中未观察到这种情况。在稳定表达显性负性Stat3蛋白的YCU-891细胞衍生物中,VEGF mRNA和VEGF蛋白的细胞水平显著受到抑制。在从舌癌患者获得的51份临床样本中,Stat3蛋白磷酸化(激活)形式的表达水平与VEGF产生(P<0.05)和肿瘤内微血管密度IMVD(P<0.01)显著相关。这些结果强烈表明,Stat3直接上调VEGF转录,从而促进HNSCC中的血管生成。抑制Stat3活性可能为HNSCC提供一种新的抗血管生成疗法。